ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ: SCRX) today announced the pricing of its offering of $285 million principal amount of 2.625% Contingent Convertible Senior Notes due 2027 (which represents a $35 million increase in the offering size originally announced). The Company has granted the underwriters a 13-day option to purchase up to an additional $40.0 million of the notes to cover over-allotments, if any. The Company intends to use the proceeds of the offering to redeem all of its $150 million 1.75% Contingent Convertible Senior Subordinated Notes Due 2024, for future acquisitions or licenses of products and technologies, and for capital expenditures and general corporate purposes.
